Chantix might not increase heart risk, review shows

Pfizer's smoking-cessation treatment Chantix might not increase the risk of heart attack and other serious heart conditions, as was reported in a 2011 study, according to a review that looked at data on 9,232 people treated for three months. Researcher Judith Prochaska said the first study was misleading because "findings were inflated, and they were just focusing on that relative risk." Only 0.63% of 5,431 individuals developed a serious heart problem.

View Full Article in:

Review finds Chantix may not raise heart risks - Reuters

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Food & Drug Associate
Confidential
Washington, D.C., DC
Senior Manager, Gaps in Care
UAW Retiree Medical Benefits Trust
Detroit, MI
Compliance Director
Abbott Laboratories
Santa Clara, CA
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations